Lista de obras -

A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2011

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

artículo científico publicado en 2017

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

artículo científico publicado en 2014

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 12 de octubre de 2010

An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

artículo científico publicado en 2015

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

artículo científico publicado en 2016

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer ⬇️

artículo científico publicado el 15 de junio de 2010

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

artículo científico

Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy

artículo científico publicado en 2016

Complications of therapy in cancer patients: Case 2. Scrotal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia

artículo científico publicado en 2004

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

artículo científico publicado en 2017

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer ⬇️

artículo científico publicado el 13 de septiembre de 2010

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

artículo científico publicado en 2014

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

artículo científico publicado en 2018

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

artículo científico publicado en 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

artículo científico publicado en 2011

High SOX2 levels predict better outcome in non-small cell lung carcinomas

artículo científico publicado en 2013

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

artículo científico publicado en 2010

High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma

artículo científico publicado en 2009

Immune checkpoint modulation for non-small cell lung cancer

artículo científico publicado en 2015

Immune therapies for lung cancer

artículo científico publicado en 2012

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

artículo científico publicado en 2017

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1.

artículo científico publicado en 2013

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.

artículo científico publicado en 2018

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy

artículo científico publicado en 2016

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

artículo científico publicado en 2016

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

artículo científico publicado en 2014

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

artículo científico publicado en 2009

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

artículo científico publicado en 2017

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

artículo científico publicado en 2016

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

artículo científico publicado en 2015

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

artículo científico publicado en 2014

Targeted therapy in advanced non-small-cell lung cancer

scientific article published on June 2008

Treatment of lung cancer in older patients

artículo científico publicado en 2007

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

artículo científico publicado en 2013

Lista de obras de

A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer ⬇️

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer ⬇️

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy

Complications of therapy in cancer patients: Case 2. Scrotal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer ⬇️

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

High SOX2 levels predict better outcome in non-small cell lung carcinomas

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma

Immune checkpoint modulation for non-small cell lung cancer

Immune therapies for lung cancer

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Targeted therapy in advanced non-small-cell lung cancer

Treatment of lung cancer in older patients

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines